ClinicalTrials.gg
CompletedNCT05330975RSVictoryUpdated Dec 30, 2025Results posted

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

A Phase 3 interventional study of Placebo and mRNA-1345 in Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 62 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,317
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases — none open to participants now, none under way, none of them phase 3. mRNA-1345 respiratory syncytial virus vaccine · Virus Diseases.

Enrollment
2nd of 10
3,317 · median 579
Started
2022
with 2 others
Phase 3
4 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
10 of 10
ModernaTX, Inc.

Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, this one is the 2nd largest by enrollment, is one of 3 that started in 2022, is one of 4 in phase 3, and was the 3rd registered.

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.

Browse Virus Diseases studies →

Open to participants now

None of the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases is open now. The open studies under Virus Diseases, anywhere →

About mRNA-1345 respiratory syncytial virus vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases as a file.
02

Study summary

The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of coadministered influenza vaccine on the immune response to RSV-A; and to evaluate the impact of coadministered RSV vaccine on the immune response to influenza.

The main purposes of Part B of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with mRNA-1273.214; to evaluate the effect of coadministered mRNA-1273.214 on the immune response to RSV-A; and to evaluate the effect of coadministered RSV vaccine on the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The main purposes of Part C (single arm, open-label) of this study are to evaluate the safety and tolerability of a booster dose (BD) of mRNA-1345 administered at 1 Year following a primary dose; to evaluate the immune response to RSV-A of a BD of mRNA 1345 administered at 1 Year following a primary dose; and to evaluate the immune response to RSV-B of a BD of mRNA-1345 administered at 1 Year following a primary dose.

03

Conditions studied

  • Respiratory Syncytial Virus

Browse trials for

Keywords

  • Viral Diseases
  • Messenger RNA
  • Moderna
  • mRNA-1345
  • Respiratory syncytial virus
  • Safety
  • Vaccines
  • SARS-CoV-2
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Parts A and B both:

  • Adults ≥50 years of age on the day of the Randomization Visit (Day 1) who are primarily responsible for self-care and activities of daily living. Participants may have one or more chronic medical diagnoses, but should be medically stable as assessed by: Absence of changes in medical therapy within 1 month due to treatment failure or toxicity; Absence of medical events qualifying as SAEs within 1 month of the planned vaccination on Day 1; and absence of known, current, and life-limiting diagnoses which, in the opinion of the investigator, would make completion of the protocol unlikely.
  • Able to comply with study requirements, including access to transportation for study visits.

Part B only:

  • Fully vaccinated for COVID-19 with an approved primary series according to the locally authorized or approved regimen. If the most recent COVID-19 vaccine was part of a primary series, it must be ≥ 150 days before (or less per local guidance) Day 1. If the most recent COVID-19 vaccine was a booster dose, it must be ≥ 120 days before (or less per local guidance) Day 1.

Part C:

  • Participants at Part C study sites who have been enrolled in Part B (Groups 4 and 5) of this study; have immunogenicity blood sampling at Part B baseline and Day 29; completed the Day 211/end-of-study visits for Part B; were included in the per-protocol (PP) set; and received 1 dose of mRNA-1345 at least 12 months (but no later than 15 months) prior to the time of enrollment.
  • Able to comply with study requirements, including access to transportation for study visits.

Key Exclusion Criteria:

Part A:

  • Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to study injections (Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections.
  • Prior participation in research involving receipt of any product (drug/biologic/device including any investigational RSV product) within 45 days before the planned date of the Day 1 study injection.
  • Participant has received a seasonal influenza vaccine or any other investigational influenza vaccine ≤180 days prior to the Randomization Visit (Day 1).
  • History of a serious reaction to any prior vaccination, or Guillain-Barré syndrome within 6 weeks of any prior influenza immunization.
  • Participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study.

Part B:

  • Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤ 28 days prior to study injections (Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections (with the exception of SARS-Cov-2 vaccination).
  • Prior participation in research involving receipt of any investigational product (drug/biologic/device with the exception of RSV investigation products) within 45 days before the planned date of the Day 1 study injection.
  • Prior receipt of any investigational/approved RSV product within 1 year of the Day 1 study injection.
  • Has known history of SARS-CoV-2 infection within 90 days prior to enrollment.

Parts A and B both:

  • Participant had significant exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 10 days, as defined by the United States (US) Centers for Disease Control and Prevention (CDC) as a close contact of someone who has had COVID-19.

Part C:

  • Participation in another interventional clinical research study where participant has received an investigational product (drug/biologic/device) within 6 months before the planned date of the BD Day 1 study injection. Any prior receipt of an investigational or approved vaccine against RSV, except as part of mRNA-1345 Study P302 Part B, is exclusionary.
  • Participant has received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to the study injection (BD Day 1) or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections.
  • History of a serious reaction to any prior vaccination or Guillain-Barré syndrome 6 weeks after any prior influenza immunization.

Other inclusion and/or exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,317 participants (actual)

Study arms

  • Experimental
    Part A: mRNA-1345 + Placebo

    Single injection of mRNA-1345 and placebo, administered intramuscularly (IM), one in each arm on Day 1.

    Biological: Placebo · Biological: mRNA-1345

  • Experimental
    Part A: mRNA-1345 + Afluria® Quadrivalent

    Single injection of mRNA-1345 and Afluria® quadrivalent, administered IM, one in each arm on Day 1.

    Biological: mRNA-1345 · Biological: Afluria® Quadrivalent

  • Active comparator
    Part A: Afluria® Quadrivalent + Placebo

    Single injection of Afluria® quadrivalent and placebo, administered IM, one in each arm on Day 1.

    Biological: Placebo · Biological: Afluria® Quadrivalent

  • Experimental
    Part B: mRNA-1345 + Placebo

    Single injection of mRNA-1345 and placebo, administered IM, one in each arm on Day 1. An additional injection of mRNA-1273.214, administered on Day 29.

    Biological: Placebo · Biological: mRNA-1345 · Biological: mRNA-1273.214

  • Experimental
    Part B: mRNA-1345 + mRNA-1273.214

    Single injection of mRNA-1345 and mRNA-1273.214, administered IM, one in each arm on Day 1. An additional injection of placebo administered on Day 29.

    Biological: Placebo · Biological: mRNA-1345 · Biological: mRNA-1273.214

  • Active comparator
    Part B: mRNA-1273.214 + Placebo

    Single injection of mRNA-1273.214 and placebo, administered IM, one in each arm on Day 1. An additional injection of placebo administered on Day 29.

    Biological: Placebo · Biological: mRNA-1273.214

  • Experimental
    Part C: mRNA-1345

    Single injection of mRNA-1345 administered IM on BD Day 1.

    Biological: mRNA-1345

Interventions

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

  • BiologicalmRNA-1345

    Sterile liquid for injection

  • BiologicalAfluria® Quadrivalent

    single-dose, pre-filled syringe for injection

  • BiologicalmRNA-1273.214

    Sterile liquid for injection

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection

    Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Within 7 days after Day 1 injection

  2. Part A: Number of Participants With Unsolicited Adverse Events (AEs) After Day 1 Injection

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 1 through Day 28 (28 days after Day 1 injection)

  3. Part A: Number of Participants With Medically Attended AEs (MAAEs), SAEs, Adverse Events of Special Interest (AESIs), and AEs Leading to Withdrawal

    A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 1 through Day 181 (end of Study Part A)

  4. Part A: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) Neutralizing Antibodies (NAbs) at Day 29

    Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 international units (IU)/milliliter (mL) and ULOQ was 259061 IU/mL for RSV-A. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 29

  5. Part A: Percentage of Participants With Seroresponse in RSV-A NAbs at Day 29

    Seroresponse was defined as ≥4 × lower limit of quantification (LLOQ) if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 29

  6. Part A: GMT of Serum Anti-hemagglutination (HA) Ab Level, as Measured by Hemagglutination Inhibition (HAI) Assay for Influenza at Day 29

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.

    Time frame: Day 29

  7. Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 1 Injection

    Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Within 7 days after Day 1 injection

  8. Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 29 Injection

    Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Within 7 days after Day 29 injection

  9. Part B: Number of Participants With Unsolicited AEs After Day 1 Injection

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 1 through Day 28 (28 days after Day 1 injection)

  10. Part B: Number of Participants With Unsolicited AEs After Day 29 Injection

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 29 through Day 57 (28 days after Day 29 injection)

  11. Part B: Number of Participants With MAAEs, SAEs, AESIs, and AEs Leading to Withdrawal

    A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Day 1 through Day 211

  12. Part B: GMT of Serum RSV-A at Day 29

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 29

  13. Part B: Percentage of Participants With Seroresponse for RSV-A Neutralizing Abs From Baseline to Day 29

    Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Baseline to Day 29

  14. Part B: Geometric Mean Concentration (GMC) of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 29

    The model-based GM titer was estimated on ANCOVA model. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 arbitrary units (AU)/milliliters (mL) and ULOQ was 111433 AU/mL for Wuhan-Hu-1. LLOQ was 8 and ULOQ was B.1.1.529 for B1.1.529. As prespecified, only arms where participants received mRNA-1273.214 are presented for this outcome measure.

    Time frame: Day 29

  15. Part B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs From Baseline to Day 29

    Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. mRNA-As prespecified, only arms where participants received mRNA-1273.214 are presented for this outcome measure.

    Time frame: Baseline to Day 29

  16. Part C: Number of Participants With Solicited Local and Systemic Within 7 Days After Revaccination Day 1

    Solicited ARs were collected in an electronic eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Within 7 days after Day 1 revaccination

  17. Part C: Number of Participants With Unsolicited AEs Within 28 Days After Revaccination Day 1

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Revaccination Day 1 through Day 28 (28 days after revaccination Day 1)

  18. Part C: Number of Participants With MAAEs

    A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner.

    Time frame: Revaccination Day 1 through Day 181

  19. Part C: Number of Participants With SAEs, AESIs, and AEs Leading to Withdrawal

    An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: Revaccination Day 1 through Day 361

  20. Part C: GMT of Serum RSV-A and RSV-B NAbs mRNA-1345 Revaccination Day 29 Compared to Primary Vaccination Day 29

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 IU/mL for RSV-B. mRNA-1345 Revaccination Day 29 and mRNA-1345 primary vaccination Day 29 (received in Part B) are presented.

    Time frame: Primary Vaccination Day 29 to Revaccination Day 29

Secondary outcomes

  1. Part A: GMT of Serum RSV-B NAbs at Day 29

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 29

  2. Part A: Percentage of Participants With Seroresponse in RSV-B NAbs at Day 29

    Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 29

  3. Part A: Percentage of Participants With Seroconversion in Influenza A and B Strains at Day 181

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Seroconversion was defined as a titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline in the titers if Baseline was ≥1:10. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.

    Time frame: Day 181

  4. Part A: GMT of Serum RSV-A and RSV-B NAbs at Day 181

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 181

  5. Part A: Geometric Mean Fold Rise (GMFR) of Serum RSV-A and RSV-B NAbs at Day 181

    95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 181

  6. Part A: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAb Titers at Day 181

    Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ.As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 181

  7. Part A: Percentage of Participants With ≥2-fold Increases From Baseline in RSV-A and RSV-B NAb Titers at Day 181

    ≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Baseline to Day 181

  8. Part A: GMT of Serum Anti-HA Ab Level, as Measured by HAI Assay for Influenza at Day 181

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.

    Time frame: Day 181

  9. Part A: GMFR of Serum Anti-HA Ab Level, as Measured by HAI Assay for Influenza at Day 181

    Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B. 95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.

    Time frame: Day 181

  10. Part B: GMT of Serum RSV-B NAbs at Day 29

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 29

  11. Part B: Percentage of Participants With Seroresponse in RSV-B NAbs From Baseline to Day 29

    Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Baseline to Day 29

  12. Part B: GMT of Serum RSV-A and RSV-B NAbs at Day 181

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 181

  13. Part B: GMFR of Serum RSV-A and RSV-B NAbs at Day 181

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 181

  14. Part B: GMC of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 181

    95% CI for GM value was calculated based on the t-distribution of the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for Wuhan-Hu-1. LLOQ was 8 AU/mL and ULOQ was 24503 for B1.1.529.

    Time frame: Day 181

  15. Part B: GMFR of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 181

    95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

    Time frame: Day 181

  16. Part B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs From Baseline to Day 181

    Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 111433 for Wuhan-Hu-1. LLOQ was 8 and ULOQ was B.1.1.529 for B1.1.529.

    Time frame: Baseline to Day 181

  17. Part B: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAb Titers at Day 181

    Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 181

  18. Part B: Percentage of Participants With ≥2-fold Increases From Baseline in RSV-A and RSV-B NAb Titers at Day 181

    ≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Baseline to Day 181

  19. Part B: GMT of Serum RSV-A and RSV-B NAbs at Day 211

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 211

  20. Part B: GMFR of Serum RSV-A and RSV-B NAbs at Day 211

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 211

  21. Part B: GMC of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 211

    95% CI for GM value was calculated based on the t-distribution of the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for Wuhan-Hu-1. LLOQ was 8 AU/mL and ULOQ was 24503 for B1.1.529.

    Time frame: Day 211

  22. Part B: GMFR of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 211

    95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

    Time frame: Day 211

  23. Part B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs at Day 211

    Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 111433 for Wuhan-Hu-1. LLOQ was 8 and ULOQ was B.1.1.529 for B1.1.529.

    Time frame: Day 211

  24. Part B: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAb Titers at Day 211

    Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 211

  25. Part B: Percentage of Participants With ≥2-fold Increases From Baseline in RSV-A and RSV-B NAb Titers at Day 211

    ≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

    Time frame: Day 211

  26. Part C: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAbs From Baseline (Before Primary Vaccination) to Revaccination Day 29

    Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. Primary vaccination Day 29 (received in Part B) and Revaccination Day 29 are presented.

    Time frame: Baseline (Before Primary Vaccination in Part B) to Revaccination Day 29

  27. Part C: GMT of Serum RSV-A and RSV-B NAbs at Revaccination Day 361

    Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 IU/mL for RSV-B.

    Time frame: Revaccination Day 361

  28. Part C: GMFR of Serum RSV-A and RSV-B NAbs at Revaccination Day 361

    95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

    Time frame: Revaccination Day 361

  29. Part C: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAbs at Revaccination Day 361

    Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ.

    Time frame: Baseline to Revaccination Day 361

  30. Part C: Percentage of Participants With ≥2-fold Increases From Baseline (Before Primary Vaccination) in RSV-A and RSV-B NAb Titers at Revaccination Day 361

    ≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 IU/mL for RSV-B.

    Time frame: Baseline to Revaccination Day 361

Other outcomes

  1. Number of Deaths During the Study

    A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable and/or the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

    Time frame: Up to Day 181 for Part A, up to Day 211 for Part B, and up to Day 361 for Part C

07

Results

Posted Dec 30, 2025

Participant flow

Primary
Participant flow — Primary
MilestonePart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + PlaceboPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + PlaceboPart C: mRNA-1345 Revaccination
Started2496906925605645620
Received at least 1 dose of any study injection2496856895565625580
Part b day 1 injection0005565625580
Part b day 29 injection0005305355360
Safety set2496856895545625600
Solicited safety set (day 1 injection)2496786835535625570
Part b solicited safety set day 29 injection0005225325280
Per-protocol (pp) set2326396265135145190
Completed2336526435005165100
Not completed1638496048520
Withdrew: Lost to follow-up1221383025280
Withdrew: Withdrawal by subject41182320190
Withdrew: Protocol violation0204030
Withdrew: Death0311000
Withdrew: Other than specified0121220
Withdrew: Adverse event0001000
Withdrew: Physician decision0000100
Revaccination
Participant flow — Revaccination
MilestonePart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + PlaceboPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + PlaceboPart C: mRNA-1345 Revaccination
Started000000543
Part c safety set000000543
Part c solicited safety set000000543
Part c pp set000000525
Completed000000525
Not completed00000018
Withdrew: Adverse event0000003
Withdrew: Lost to follow-up00000010
Withdrew: Withdrawal by subject0000002
Withdrew: Death0000003

Outcome measures

SecondaryPart A: GMT of Serum RSV-B NAbs at Day 29

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 29
Reported as:
Geometric mean · IU/mL
Part A: GMT of Serum RSV-B NAbs at Day 29
IU/mLPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® Quadrivalent
Part A: GMT of Serum RSV-B NAbs at Day 2910436.03 (8973.29 to 12137.20)8909.80 (8016.02 to 9903.24)
Statistical analysis
  • Part A: mRNA-1345 + Placebo vs Part A: mRNA-1345 + Afluria® Quadrivalent · Gmr: 0.854 · 95% CI 0.728 to 1.002mRNA-1345+Afluria group compared mRNA-1345 alone group
SecondaryPart A: Percentage of Participants With Seroresponse in RSV-B NAbs at Day 29

Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With Seroresponse in RSV-B NAbs at Day 29
percentage of participantsPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® Quadrivalent
Part A: Percentage of Participants With Seroresponse in RSV-B NAbs at Day 2963.8 (57.2 to 70.0)49.5 (45.5 to 53.4)
Statistical analysis
  • Part A: mRNA-1345 + Placebo vs Part A: mRNA-1345 + Afluria® Quadrivalent · Difference: -14.3 · 95% CI -21.5 to -6.9mRNA-1345+Afluria group compared mRNA-1345 alone group
SecondaryPart A: Percentage of Participants With Seroconversion in Influenza A and B Strains at Day 181

Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Seroconversion was defined as a titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline in the titers if Baseline was ≥1:10. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.

Time frame:
Day 181
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With Seroconversion in Influenza A and B Strains at Day 181
percentage of participantsPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + Placebo
Influenza A H1N1 Antibody41.1 (37.1 to 45.1)38.8 (34.9 to 42.9)
Influenza A H3N2 Antibody29.4 (25.8 to 33.2)28.7 (25.1 to 32.6)
Influenza B Washington Antibody19.5 (16.5 to 22.9)19.7 (16.5 to 23.1)
Influenza B Phuket Antibody17.2 (14.3 to 20.5)18.8 (15.8 to 22.2)
SecondaryPart A: GMT of Serum RSV-A and RSV-B NAbs at Day 181

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 181
Reported as:
Geometric mean · IU/mL
Part A: GMT of Serum RSV-A and RSV-B NAbs at Day 181
IU/mLPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® Quadrivalent
RSV-A7551.13 (6504.13 to 8766.68)6429.48 (5850.16 to 7066.17)
RSV-B2402.86 (2120.18 to 2723.23)2301.47 (2114.95 to 2504.44)
SecondaryPart A: Geometric Mean Fold Rise (GMFR) of Serum RSV-A and RSV-B NAbs at Day 181

95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 181
Reported as:
Geometric mean · ratio
Part A: Geometric Mean Fold Rise (GMFR) of Serum RSV-A and RSV-B NAbs at Day 181
ratioPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® Quadrivalent
RSV-A3.46 (2.97 to 4.04)2.19 (1.99 to 2.40)
RSV-B1.32 (1.17 to 1.49)0.94 (0.87 to 1.02)
SecondaryPart A: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAb Titers at Day 181

Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ.As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 181
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAb Titers at Day 181
percentage of participantsPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® Quadrivalent
RSV-A46.8 (40.0 to 53.6)29.9 (26.3 to 33.7)
RSV-B13.3 (9.1 to 18.5)6.7 (4.8 to 9.0)
SecondaryPart A: Percentage of Participants With ≥2-fold Increases From Baseline in RSV-A and RSV-B NAb Titers at Day 181

≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Baseline to Day 181
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With ≥2-fold Increases From Baseline in RSV-A and RSV-B NAb Titers at Day 181
percentage of participantsPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® Quadrivalent
RSV-A67.0 (60.3 to 73.2)54.1 (50.0 to 58.1)
RSV-B32.1 (26.0 to 38.7)21.0 (17.9 to 24.5)
SecondaryPart A: GMT of Serum Anti-HA Ab Level, as Measured by HAI Assay for Influenza at Day 181

Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.

Time frame:
Day 181
Reported as:
Geometric mean · titer
Part A: GMT of Serum Anti-HA Ab Level, as Measured by HAI Assay for Influenza at Day 181
titerPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + Placebo
Influenza A H1N1 Antibody155.59 (138.10 to 175.31)156.47 (139.65 to 175.33)
Influenza A H3N2 Antibody113.58 (101.54 to 127.06)109.36 (98.28 to 121.68)
Influenza B Washington Antibody32.11 (29.10 to 35.43)35.03 (31.76 to 38.64)
Influenza B Phuket Antibody25.64 (23.34 to 28.17)26.43 (24.17 to 28.91)
SecondaryPart A: GMFR of Serum Anti-HA Ab Level, as Measured by HAI Assay for Influenza at Day 181

Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B. 95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.

Time frame:
Day 181
Reported as:
Geometric mean · ratio
Part A: GMFR of Serum Anti-HA Ab Level, as Measured by HAI Assay for Influenza at Day 181
ratioPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + Placebo
Influenza A H1N1 Antibody3.21 (2.80 to 3.68)3.08 (2.70 to 3.51)
Influenza A H3N2 Antibody2.28 (2.04 to 2.55)2.23 (2.00 to 2.49)
Influenza B Washington Antibody1.80 (1.66 to 1.96)1.95 (1.79 to 2.13)
Influenza B Phuket Antibody1.76 (1.63 to 1.90)1.79 (1.66 to 1.93)
SecondaryPart B: GMT of Serum RSV-B NAbs at Day 29

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 29
Reported as:
Geometric mean · IU/mL
Part B: GMT of Serum RSV-B NAbs at Day 29
IU/mLPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + Placebo
Part B: GMT of Serum RSV-B NAbs at Day 296584.54 (5961.73 to 7272.40)5843.94 (5292.14 to 6453.28)
Statistical analysis
  • Part B: mRNA-1345 + Placebo + mRNA-1273.214 vs Part B: mRNA-1345 + mRNA-1273.214 + Placebo · Gmr: 0.888 · 95% CI 0.791 to 0.995mRNA-1345+mRNA-1273.214 compared with mRNA-1345 alone
SecondaryPart B: Percentage of Participants With Seroresponse in RSV-B NAbs From Baseline to Day 29

Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Baseline to Day 29
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With Seroresponse in RSV-B NAbs From Baseline to Day 29
percentage of participantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + Placebo
Part B: Percentage of Participants With Seroresponse in RSV-B NAbs From Baseline to Day 2951.9 (47.4 to 56.3)46.0 (41.6 to 50.4)
Statistical analysis
  • Part B: mRNA-1345 + Placebo + mRNA-1273.214 vs Part B: mRNA-1345 + mRNA-1273.214 + Placebo · Difference: -5.9 · 95% CI -11.9 to 0.3mRNA-1345+mRNA-1273.214 compared with mRNA-1345 alone
SecondaryPart B: GMT of Serum RSV-A and RSV-B NAbs at Day 181

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 181
Reported as:
Geometric mean · IU/mL
Part B: GMT of Serum RSV-A and RSV-B NAbs at Day 181
IU/mLPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + Placebo
RSV-A6456.32 (5830.84 to 7148.91)5221.87 (4723.14 to 5773.26)
RSV-B2447.67 (2236.91 to 2678.28)2274.83 (2070.95 to 2498.79)
SecondaryPart B: GMFR of Serum RSV-A and RSV-B NAbs at Day 181

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 181
Reported as:
Geometric mean · ratio
Part B: GMFR of Serum RSV-A and RSV-B NAbs at Day 181
ratioPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + Placebo
RSV-A2.91 (2.65 to 3.20)2.58 (2.36 to 2.82)
RSV-B1.61 (1.48 to 1.75)1.49 (1.38 to 1.61)
SecondaryPart B: GMC of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 181

95% CI for GM value was calculated based on the t-distribution of the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for Wuhan-Hu-1. LLOQ was 8 AU/mL and ULOQ was 24503 for B1.1.529.

Time frame:
Day 181
Reported as:
Geometric mean · AU/mL
Part B: GMC of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 181
AU/mLPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
Wuhan-Hu-14075.34 (3722.53 to 4461.58)3615.45 (3272.04 to 3994.91)3665.39 (3335.37 to 4028.07)
B.1.1.5291002.35 (894.17 to 1123.61)889.75 (791.84 to 999.76)919.49 (820.46 to 1030.46)
SecondaryPart B: GMFR of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 181

95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

Time frame:
Day 181
Reported as:
Geometric mean · ratio
Part B: GMFR of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 181
ratioPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
Wuhan-Hu-12.12 (1.90 to 2.38)1.94 (1.72 to 2.19)1.84 (1.65 to 2.06)
B.1.1.5293.57 (3.12 to 4.09)3.27 (2.83 to 3.78)3.13 (2.75 to 3.55)
SecondaryPart B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs From Baseline to Day 181

Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 111433 for Wuhan-Hu-1. LLOQ was 8 and ULOQ was B.1.1.529 for B1.1.529.

Time frame:
Baseline to Day 181
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs From Baseline to Day 181
percentage of participantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
Wuhan-Hu-124.1 (20.3 to 28.2)23.6 (19.9 to 27.7)19.8 (16.4 to 23.7)
B.1.1.52944.7 (40.2 to 49.3)41.0 (36.6 to 45.6)40.5 (36.1 to 45.0)
SecondaryPart B: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAb Titers at Day 181

Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 181
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAb Titers at Day 181
percentage of participantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + Placebo
RSV-A34.9 (30.6 to 39.3)30.2 (26.1 to 34.5)
RSV-B14.9 (11.9 to 18.5)12.7 (9.9 to 16.0)
SecondaryPart B: Percentage of Participants With ≥2-fold Increases From Baseline in RSV-A and RSV-B NAb Titers at Day 181

≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Baseline to Day 181
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With ≥2-fold Increases From Baseline in RSV-A and RSV-B NAb Titers at Day 181
percentage of participantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + Placebo
RSV-A62.8 (58.3 to 67.2)58.3 (53.8 to 62.7)
RSV-B36.4 (32.1 to 40.9)35.7 (31.5 to 40.2)
SecondaryPart B: GMT of Serum RSV-A and RSV-B NAbs at Day 211

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 211
Reported as:
Geometric mean · IU/mL
Part B: GMT of Serum RSV-A and RSV-B NAbs at Day 211
IU/mLPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + Placebo
RSV-A5921.09 (5357.33 to 6544.17)4696.74 (4245.92 to 5195.44)
RSV-B2261.26 (2069.70 to 2470.56)2132.70 (1943.36 to 2340.49)
SecondaryPart B: GMFR of Serum RSV-A and RSV-B NAbs at Day 211

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 211
Reported as:
Geometric mean · ratio
Part B: GMFR of Serum RSV-A and RSV-B NAbs at Day 211
ratioPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + Placebo
RSV-A2.71 (2.48 to 2.98)2.35 (2.15 to 2.56)
RSV-B1.50 (1.39 to 1.63)1.40 (1.30 to 1.51)
SecondaryPart B: GMC of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 211

95% CI for GM value was calculated based on the t-distribution of the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 AU/mL and ULOQ was 111433 AU/mL for Wuhan-Hu-1. LLOQ was 8 AU/mL and ULOQ was 24503 for B1.1.529.

Time frame:
Day 211
Reported as:
Geometric mean · AU/mL
Part B: GMC of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 211
AU/mLPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
Wuhan-Hu-13551.74 (3245.10 to 3887.35)3034.11 (2743.48 to 3355.54)3123.69 (2841.55 to 3433.84)
B.1.1.529923.10 (826.89 to 1030.51)797.17 (708.18 to 897.33)795.90 (709.19 to 893.21)
SecondaryPart B: GMFR of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 211

95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

Time frame:
Day 211
Reported as:
Geometric mean · ratio
Part B: GMFR of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 211
ratioPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
Wuhan-Hu-11.87 (1.66 to 2.09)1.64 (1.45 to 1.85)1.59 (1.42 to 1.77)
B.1.1.5293.31 (2.90 to 3.79)2.95 (2.56 to 3.40)2.72 (2.39 to 3.10)
SecondaryPart B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs at Day 211

Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 111433 for Wuhan-Hu-1. LLOQ was 8 and ULOQ was B.1.1.529 for B1.1.529.

Time frame:
Day 211
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs at Day 211
percentage of participantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
Wuhan-Hu-121.1 (17.5 to 25.1)20.3 (16.7 to 24.1)17.8 (14.5 to 21.5)
B.1.1.52941.4 (36.9 to 46.0)38.8 (34.4 to 43.3)37.0 (32.7 to 41.5)
SecondaryPart B: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAb Titers at Day 211

Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 211
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAb Titers at Day 211
percentage of participantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + Placebo
RSV-A32.5 (28.3 to 36.9)26.5 (22.7 to 30.7)
RSV-B12.3 (9.5 to 15.6)10.1 (7.5 to 13.1)
SecondaryPart B: Percentage of Participants With ≥2-fold Increases From Baseline in RSV-A and RSV-B NAb Titers at Day 211

≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 for RSV-B. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 211
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With ≥2-fold Increases From Baseline in RSV-A and RSV-B NAb Titers at Day 211
percentage of participantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + Placebo
RSV-A57.8 (53.2 to 62.3)53.7 (49.2 to 58.2)
RSV-B33.7 (29.4 to 38.1)30.6 (26.5 to 34.9)
SecondaryPart C: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAbs From Baseline (Before Primary Vaccination) to Revaccination Day 29

Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. Primary vaccination Day 29 (received in Part B) and Revaccination Day 29 are presented.

Time frame:
Baseline (Before Primary Vaccination in Part B) to Revaccination Day 29
Reported as:
Number · percentage of participants
Part C: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAbs From Baseline (Before Primary Vaccination) to Revaccination Day 29
percentage of participantsPart C: mRNA-1345 Primary VaccinationPart C: mRNA-1345 Revaccincation
RSV-A75.3 (71.3 to 78.9)77.5 (73.7 to 81.0)
RSV-B48.2 (43.8 to 52.6)47.5 (43.2 to 51.9)
SecondaryPart C: GMT of Serum RSV-A and RSV-B NAbs at Revaccination Day 361

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 IU/mL for RSV-B.

Time frame:
Revaccination Day 361
Reported as:
Geometric mean · IU/mL
Part C: GMT of Serum RSV-A and RSV-B NAbs at Revaccination Day 361
IU/mLPart C: mRNA-1345 Revaccincation
RSV-A4708.27 (4279.78 to 5179.67)
RSV-B2251.24 (2054.09 to 2467.32)
SecondaryPart C: GMFR of Serum RSV-A and RSV-B NAbs at Revaccination Day 361

95% CI for GMFR (postinjection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.

Time frame:
Revaccination Day 361
Reported as:
Geometric mean · ratio
Part C: GMFR of Serum RSV-A and RSV-B NAbs at Revaccination Day 361
ratioPart C: mRNA-1345 Revaccincation
RSV-A2.26 (2.06 to 2.48)
RSV-B1.42 (1.31 to 1.53)
SecondaryPart C: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAbs at Revaccination Day 361

Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ.

Time frame:
Baseline to Revaccination Day 361
Reported as:
Number · percentage of participants
Part C: Percentage of Participants With Seroresponse in RSV-A and RSV-B NAbs at Revaccination Day 361
percentage of participantsPart C: mRNA-1345 Revaccincation
RSV-A25.8 (22.0 to 29.9)
RSV-B11.5 (8.8 to 14.6)
SecondaryPart C: Percentage of Participants With ≥2-fold Increases From Baseline (Before Primary Vaccination) in RSV-A and RSV-B NAb Titers at Revaccination Day 361

≥2-fold increase from baseline at participant level was defined as a change from below the LLOQ to equal or above 2 \* LLOQ, or at least a 2-fold increase if baseline was equal to or above the LLOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 IU/mL for RSV-B.

Time frame:
Baseline to Revaccination Day 361
Reported as:
Number · percentage of participants
Part C: Percentage of Participants With ≥2-fold Increases From Baseline (Before Primary Vaccination) in RSV-A and RSV-B NAb Titers at Revaccination Day 361
percentage of participantsPart C: mRNA-1345 Revaccincation
RSV-A53.0 (48.5 to 57.5)
RSV-B32.7 (28.5 to 37.0)
PrimaryPart A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection

Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Within 7 days after Day 1 injection
Reported as:
Count of participants · Participants
Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection
ParticipantsPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + Placebo
Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection147395291
PrimaryPart A: Number of Participants With Unsolicited Adverse Events (AEs) After Day 1 Injection

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 1 through Day 28 (28 days after Day 1 injection)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Unsolicited Adverse Events (AEs) After Day 1 Injection
ParticipantsPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + Placebo
Part A: Number of Participants With Unsolicited Adverse Events (AEs) After Day 1 Injection215746
PrimaryPart A: Number of Participants With Medically Attended AEs (MAAEs), SAEs, Adverse Events of Special Interest (AESIs), and AEs Leading to Withdrawal

A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 1 through Day 181 (end of Study Part A)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Medically Attended AEs (MAAEs), SAEs, Adverse Events of Special Interest (AESIs), and AEs Leading to Withdrawal
ParticipantsPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + Placebo
MAAE41136114
SAE42824
AESI011
AEs Leading to Withdrawal031
PrimaryPart A: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) Neutralizing Antibodies (NAbs) at Day 29

Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 international units (IU)/milliliter (mL) and ULOQ was 259061 IU/mL for RSV-A. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 29
Reported as:
Geometric mean · IU/mL
Part A: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) Neutralizing Antibodies (NAbs) at Day 29
IU/mLPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® Quadrivalent
Part A: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) Neutralizing Antibodies (NAbs) at Day 2917271.72 (14448.78 to 20646.20)13929.98 (12291.04 to 15787.47)
Statistical analysis
  • Part A: mRNA-1345 + Placebo vs Part A: mRNA-1345 + Afluria® Quadrivalent · Gmr: 0.807 · 95% CI 0.668 to 0.974mRNA-1345+Afluria group compared mRNA-1345 alone group
PrimaryPart A: Percentage of Participants With Seroresponse in RSV-A NAbs at Day 29

Seroresponse was defined as ≥4 × lower limit of quantification (LLOQ) if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Part A: Percentage of Participants With Seroresponse in RSV-A NAbs at Day 29
percentage of participantsPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® Quadrivalent
Part A: Percentage of Participants With Seroresponse in RSV-A NAbs at Day 2972.4 (66.2 to 78.1)61.2 (57.3 to 65.0)
Statistical analysis
  • Part A: mRNA-1345 + Placebo vs Part A: mRNA-1345 + Afluria® Quadrivalent · Difference: -11.2 · 95% CI -17.9 to -4.1mRNA-1345+Afluria group compared mRNA-1345 alone group
PrimaryPart A: GMT of Serum Anti-hemagglutination (HA) Ab Level, as Measured by Hemagglutination Inhibition (HAI) Assay for Influenza at Day 29

Influenza A strains included H1N1 and H3N2 and influenza B strains included Washington and Phuket strains. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 and ULOQ was 2560 for Influenza A. LLOQ was 10 and ULOQ was 640 for Influenza B. As prespecified, only arms where participants received Afluria® Quadrivalent are presented for this outcome measure.

Time frame:
Day 29
Reported as:
Geometric mean · titer
Part A: GMT of Serum Anti-hemagglutination (HA) Ab Level, as Measured by Hemagglutination Inhibition (HAI) Assay for Influenza at Day 29
titerPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + Placebo
Influenza A H1N1 Antibody271.27 (239.71 to 306.99)303.92 (268.24 to 344.35)
Influenza A H3N2 Antibody144.14 (130.37 to 159.36)148.69 (134.35 to 164.55)
Influenza B Washington Antibody57.59 (52.01 to 63.77)62.13 (56.05 to 68.86)
Influenza B Phuket Antibody38.52 (34.91 to 42.50)42.40 (38.39 to 46.82)
Statistical analysis
  • Part A: mRNA-1345 + Afluria® Quadrivalent vs Part A: Afluria® Quadrivalent + Placebo · Gmr: 0.893 · 95% CI 0.772 to 1.032mRNA-1345+Afluria group at Day 29 compared with the GMT of anti-HA Ab in the Afluria alone group
  • Part A: mRNA-1345 + Afluria® Quadrivalent vs Part A: Afluria® Quadrivalent + Placebo · Gmr: 0.969 · 95% CI 0.861 to 1.091mRNA-1345+Afluria group at Day 29 compared with the GMT of anti-HA Ab in the Afluria alone group
  • Part A: mRNA-1345 + Afluria® Quadrivalent vs Part A: Afluria® Quadrivalent + Placebo · Gmr: 0.927 · 95% CI 0.822 to 1.045mRNA-1345+Afluria group at Day 29 compared with the GMT of anti-HA Ab in the Afluria alone group
  • Part A: mRNA-1345 + Afluria® Quadrivalent vs Part A: Afluria® Quadrivalent + Placebo · Gmr: 0.909 · 95% CI 0.809 to 1.020mRNA-1345+Afluria group at Day 29 compared with the GMT of anti-HA Ab in the Afluria alone group
PrimaryPart B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 1 Injection

Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Within 7 days after Day 1 injection
Reported as:
Count of participants · Participants
Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 1 Injection
ParticipantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 1 Injection358394361
PrimaryPart B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 29 Injection

Solicited ARs were collected in an eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Within 7 days after Day 29 injection
Reported as:
Count of participants · Participants
Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 29 Injection
ParticipantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 29 Injection265147148
PrimaryPart B: Number of Participants With Unsolicited AEs After Day 1 Injection

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 1 through Day 28 (28 days after Day 1 injection)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Unsolicited AEs After Day 1 Injection
ParticipantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
Part B: Number of Participants With Unsolicited AEs After Day 1 Injection415444
PrimaryPart B: Number of Participants With Unsolicited AEs After Day 29 Injection

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 29 through Day 57 (28 days after Day 29 injection)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Unsolicited AEs After Day 29 Injection
ParticipantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
Part B: Number of Participants With Unsolicited AEs After Day 29 Injection312526
PrimaryPart B: Number of Participants With MAAEs, SAEs, AESIs, and AEs Leading to Withdrawal

A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Day 1 through Day 211
Reported as:
Count of participants · Participants
Part B: Number of Participants With MAAEs, SAEs, AESIs, and AEs Leading to Withdrawal
ParticipantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
MAAEs10910797
SAEs181310
AESIs527
AEs Leading to Withdrawal100
PrimaryPart B: GMT of Serum RSV-A at Day 29

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Day 29
Reported as:
Geometric mean · IU/mL
Part B: GMT of Serum RSV-A at Day 29
IU/mLPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + Placebo
Part B: GMT of Serum RSV-A at Day 2919071.03 (17130.14 to 21231.84)15171.23 (13626.94 to 16890.53)
Statistical analysis
  • Part B: mRNA-1345 + Placebo + mRNA-1273.214 vs Part B: mRNA-1345 + mRNA-1273.214 + Placebo · Gmr: 0.796 · 95% CI 0.702 to 0.901mRNA-1345+mRNA-1273.214 compared to mRNA-1345 alone
PrimaryPart B: Percentage of Participants With Seroresponse for RSV-A Neutralizing Abs From Baseline to Day 29

Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. As prespecified, only arms where participants received mRNA-1345 are presented for this outcome measure.

Time frame:
Baseline to Day 29
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With Seroresponse for RSV-A Neutralizing Abs From Baseline to Day 29
percentage of participantsPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + Placebo
Part B: Percentage of Participants With Seroresponse for RSV-A Neutralizing Abs From Baseline to Day 2975.4 (71.4 to 79.1)70.9 (66.8 to 74.9)
Statistical analysis
  • Part B: mRNA-1345 + Placebo + mRNA-1273.214 vs Part B: mRNA-1345 + mRNA-1273.214 + Placebo · Difference: -4.4 · 95% CI -9.9 to 1.0mRNA-1345+mRNA-1273.214 compared to mRNA-1345 alone
PrimaryPart B: Geometric Mean Concentration (GMC) of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 29

The model-based GM titer was estimated on ANCOVA model. SARS-CoV-2 variants included Wuhan-Hu-1 and B.1.1.529. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 10 arbitrary units (AU)/milliliters (mL) and ULOQ was 111433 AU/mL for Wuhan-Hu-1. LLOQ was 8 and ULOQ was B.1.1.529 for B1.1.529. As prespecified, only arms where participants received mRNA-1273.214 are presented for this outcome measure.

Time frame:
Day 29
Reported as:
Geometric mean · AU/mL
Part B: Geometric Mean Concentration (GMC) of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 29
AU/mLPart B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
Wuhan-Hu-19881.69 (9097.35 to 10733.66)10300.49 (9490.13 to 11180.04)
B.1.1.5292353.15 (2115.26 to 2617.80)2342.87 (2107.26 to 2604.82)
Statistical analysis
  • Part B: mRNA-1345 + mRNA-1273.214 + Placebo vs Part B: mRNA-1273.214 + Placebo + Placebo · Gmr: 0.959 · 95% CI 0.872 to 1.056mRNA-1345+mRNA-1273.214 compared to mRNA-1273.214 alone
  • Part B: mRNA-1345 + mRNA-1273.214 + Placebo vs Part B: mRNA-1273.214 + Placebo + Placebo · Gmr: 1.004 · 95% CI 0.888 to 1.137mRNA-1345+mRNA-1273.214 compared to mRNA-1273.214 alone
PrimaryPart B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs From Baseline to Day 29

Seroresponse was defined as ≥4 × LLOQ if baseline was \<LLOQ or 4-fold or greater increase from baseline if baseline was ≥LLOQ. mRNA-As prespecified, only arms where participants received mRNA-1273.214 are presented for this outcome measure.

Time frame:
Baseline to Day 29
Reported as:
Number · percentage of participants
Part B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs From Baseline to Day 29
percentage of participantsPart B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + Placebo
Wuhan-Hu-152.7 (48.2 to 57.1)52.5 (48.1 to 56.9)
B.1.1.52968.4 (64.2 to 72.4)69.4 (65.2 to 73.3)
Statistical analysis
  • Part B: mRNA-1345 + mRNA-1273.214 + Placebo vs Part B: mRNA-1273.214 + Placebo + Placebo · Difference: 0.2 · 95% CI -6.0 to 6.3mRNA-1345+mRNA-1273.214 compared to mRNA-1273.214 alone
  • Part B: mRNA-1345 + mRNA-1273.214 + Placebo vs Part B: mRNA-1273.214 + Placebo + Placebo · Difference: -0.9 · 95% CI -6.6 to 4.7mRNA-1345+mRNA-1273.214 compared to mRNA-1273.214 alone
PrimaryPart C: Number of Participants With Solicited Local and Systemic Within 7 Days After Revaccination Day 1

Solicited ARs were collected in an electronic eDiary. Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered AEs. Investigator reviewed whether the solicited AR was also to be recorded as an AE. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Within 7 days after Day 1 revaccination
Reported as:
Count of participants · Participants
Part C: Number of Participants With Solicited Local and Systemic Within 7 Days After Revaccination Day 1
ParticipantsPart C: mRNA-1345 Revaccincation
Part C: Number of Participants With Solicited Local and Systemic Within 7 Days After Revaccination Day 1338
PrimaryPart C: Number of Participants With Unsolicited AEs Within 28 Days After Revaccination Day 1

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or PT/PTT) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Revaccination Day 1 through Day 28 (28 days after revaccination Day 1)
Reported as:
Count of participants · Participants
Part C: Number of Participants With Unsolicited AEs Within 28 Days After Revaccination Day 1
ParticipantsPart C: mRNA-1345 Revaccincation
Part C: Number of Participants With Unsolicited AEs Within 28 Days After Revaccination Day 131
PrimaryPart C: Number of Participants With MAAEs

A MAAE is an AE that leads to an unscheduled visit to a healthcare practitioner.

Time frame:
Revaccination Day 1 through Day 181
Reported as:
Count of participants · Participants
Part C: Number of Participants With MAAEs
ParticipantsPart C: mRNA-1345 Revaccincation
Part C: Number of Participants With MAAEs105
PrimaryPart C: Number of Participants With SAEs, AESIs, and AEs Leading to Withdrawal

An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
Revaccination Day 1 through Day 361
Reported as:
Count of participants · Participants
Part C: Number of Participants With SAEs, AESIs, and AEs Leading to Withdrawal
ParticipantsPart C: mRNA-1345 Revaccincation
SAEs28
AESIs2
AEs Leading to Withdrawal5
PrimaryPart C: GMT of Serum RSV-A and RSV-B NAbs mRNA-1345 Revaccination Day 29 Compared to Primary Vaccination Day 29

Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL and ULOQ was 259061 IU/mL for RSV-A. LLOQ was 10 IU/mL and ULOQ was 112476 IU/mL for RSV-B. mRNA-1345 Revaccination Day 29 and mRNA-1345 primary vaccination Day 29 (received in Part B) are presented.

Time frame:
Primary Vaccination Day 29 to Revaccination Day 29
Reported as:
Geometric mean · IU/mL
Part C: GMT of Serum RSV-A and RSV-B NAbs mRNA-1345 Revaccination Day 29 Compared to Primary Vaccination Day 29
IU/mLPart C: mRNA-1345 Primary VaccinationPart C: mRNA-1345 Revaccincation
RSV-A18190.30 (16467.13 to 20093.79)19649.18 (18017.92 to 21428.12)
RSV-B6746.41 (6136.32 to 7417.16)6123.47 (5599.77 to 6696.14)
Statistical analysis
  • Part C: mRNA-1345 Primary Vaccination vs Part C: mRNA-1345 Revaccincation · Gmr: 1.077 · 95% CI 0.995 to 1.166The 95% CI for the GMR is based on t-distribution of the log-transformed values then back transformed to the original scale for presentation.
  • Part C: mRNA-1345 Primary Vaccination vs Part C: mRNA-1345 Revaccincation · Gmr: 0.909 · 95% CI 0.839 to 0.984The 95% CI for the GMR is based on t-distribution of the log-transformed values then back transformed to the original scale for presentation.
Other pre-specifiedNumber of Deaths During the Study

A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable and/or the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

Time frame:
Up to Day 181 for Part A, up to Day 211 for Part B, and up to Day 361 for Part C
Reported as:
Count of participants · Participants
Number of Deaths During the Study
ParticipantsPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + PlaceboPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + PlaceboPart C: mRNA-1345 Revaccination
Deaths0311003
Deaths related to study drug0000000

Adverse events

Collected over All-cause mortality and serious adverse events were collected throughout the entire period of the study (up to Day 181 for Part A, up to Day 211 for Part B, and up to Day 361 for Part C). Other (not including serious) adverse events were collected for 28 days after the vaccination unless they met the criteria for AESIs, MAAEs or AEs led to discontinuation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: mRNA-1345 + Placebo0/249 (0%)4/249 (1.6%)0/249 (0%)
Part A: mRNA-1345 + Afluria Quadrivalent3/690 (0.4%)28/685 (4.1%)0/685 (0%)
Part A: Afluria Quadrivalent + Placebo1/692 (0.1%)24/689 (3.5%)0/689 (0%)
Part B: mRNA-1345 + Placebo + mRNA-1273.2141/560 (0.2%)18/554 (3.2%)0/554 (0%)
Part B: mRNA-1345 + mRNA-1273.214 + Placebo0/564 (0%)13/562 (2.3%)0/562 (0%)
Part B: mRNA-1273.214 + Placebo + Placebo0/562 (0%)10/560 (1.8%)0/560 (0%)
Part C: Revaccination3/543 (0.6%)28/543 (5.2%)0/543 (0%)
Most frequent serious events
Showing 10 of 121
Most frequent serious events
EventPart A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria QuadrivalentPart A: Afluria Quadrivalent + PlaceboPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + PlaceboPart C: Revaccination
CellulitisInfections and infestations0/2492/6850/6891/5542/5620/5603/543
SepsisInfections and infestations0/2493/6851/6890/5540/5620/5601/543
Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2490/6850/6890/5540/5620/5600/543
Acute myocardial infarctionCardiac disorders1/2490/6850/6890/5541/5620/5601/543
HypertensionVascular disorders1/2491/6850/6890/5540/5620/5600/543
Portal hypertensionHepatobiliary disorders1/2490/6850/6890/5540/5620/5600/543
Skin ulcerSkin and subcutaneous tissue disorders1/2490/6850/6890/5540/5620/5600/543
OsteoarthritisMusculoskeletal and connective tissue disorders1/2490/6850/6890/5540/5621/5600/543
PneumoniaInfections and infestations0/2491/6850/6892/5540/5620/5602/543
Septic shockInfections and infestations0/2490/6851/6890/5540/5620/5602/543

Baseline characteristics

Randomized Set included all participants who were randomized in the study, regardless of the participant's treatment status in the study.

Age, Customized
Age, Customized(years)Part A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + PlaceboPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + PlaceboTotal
≥50 years of age2496906925605645623317
Sex: Female, Male
Sex: Female, Male(Participants)Part A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + PlaceboPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + PlaceboTotal
Female1413673753153172961811
Male1083233172452472661506
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + PlaceboPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + PlaceboTotal
Hispanic or Latino912402492132142231230
Not Hispanic or Latino1584454423423493332069
Unknown or Not Reported05151618
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: mRNA-1345 + PlaceboPart A: mRNA-1345 + Afluria® QuadrivalentPart A: Afluria® Quadrivalent + PlaceboPart B: mRNA-1345 + Placebo + mRNA-1273.214Part B: mRNA-1345 + mRNA-1273.214 + PlaceboPart B: mRNA-1273.214 + Placebo + PlaceboTotal
Race — White1895245144304284382523
Race — Black or African American59157166112113111718
Race — Asian04368122
Race — American Indian or Alaska Native11464218
Race — Native Hawaiian or Other Pacific Islander0131308
Race — Other0111036
Race — Multiple0201036
Race — Not Reported00138416
08

Study locations

62 sites
  • Central Research Associates Inc
    Birmingham, Alabama 35205, United States
  • Del Sol Research Management - Clinedge - PPDS
    Tucson, Arizona 85715, United States
  • Paragon Rx Clinical, Inc
    Garden Grove, California 92703-1811, United States
  • Ark Clinical Research
    Long Beach, California 90806, United States
  • Long Beach Clinical Trials, LLC (Site 1)
    Long Beach, California 90806, United States
  • Long Beach Clinical Trials, LLC (Site 2)
    Long Beach, California 90806, United States
  • Central Valley Research, LLC
    Modesto, California 95350, United States
  • Velocity Clinical Research - Panorama City
    Panorama City, California 91402-3022, United States
  • Empire Clinical Research
    Pomona, California 91786, United States
  • Acclaim Clinical Research
    San Diego, California 92120, United States
  • Medical Center For Clinical Research - M3 WR - ERN - PPDS
    San Diego, California 92120, United States
  • Ark Clinical Research
    Tustin, California 92780, United States
  • Chase Medical Research LLC
    Waterbury, Connecticut 06708, United States
  • Teradan Clinical Trials
    Brandon, Florida 33511-4925, United States
  • Revival Research Corporation - Clinedge - PPDS
    Doral, Florida 33122, United States
  • Dolphin Medical Research
    Doral, Florida 33172, United States
  • Indago Research and Health Center
    Hialeah, Florida 33012, United States
  • Westside Center for Clinical Research - ERN - PPDS
    Jacksonville, Florida 32205, United States
  • Suncoast Research Group LLC - ERN-PPDS
    Miami, Florida 33135, United States
  • Suncoast Research Associates LLC - ERN - PPDS
    Miami, Florida 33173, United States
  • Floridian Clinical Research - ClinEdge - PPDS
    Miami Lakes, Florida 33016, United States
  • Tekton Research - Georgia - Platinum - PPDS
    Chamblee, Georgia 30341, United States
  • Lifeline Primary Care / CCT Research
    Lilburn, Georgia 30047-2832, United States
  • Georgia Clinic / CCT Research
    Norcross, Georgia 30092-4544, United States
  • Meridian Clinical Research (Savannah Georgia) - Platinum - PPDS
    Savannah, Georgia 31406, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Meridian Clinical Research (Sioux City - Iowa)
    Sioux City, Iowa 51106, United States
  • Meridian Clinical Research, LLC (Overland Park, Kansas) - Platinum - PPDS
    Overland Park, Kansas 66210-1863, United States
  • Meridian Clinical Research (Baton Rouge-Louisiana) - Platinum - PPDS
    Baton Rouge, Louisiana 70809, United States
  • Clinical Trials of SWLA, LLC
    Lake Charles, Louisiana 70601, United States
  • Meridian Clinical Research (Rockville Maryland) - Platinum - PPDS
    Rockville, Maryland 20854-2957, United States
  • Clinical Research Institute, Inc - CRN - PPDS
    Minneapolis, Minnesota 55402, United States
  • Meridian Clinical Research (Grand Island) - Platinum - PPDS
    Grand Island, Nebraska 68803, United States
  • Meridian Clinical Research, LLC (Lincoln Nebraska) - Platinum - PPDS
    Lincoln, Nebraska 68510, United States
  • Be Well Clinical Studies, LLC
    Lincoln, Nebraska 68516, United States
  • Meridian Clinical Research
    Norfolk, Nebraska 68701, United States
  • Meridian Clinical Research (Omaha-Nebraska) - Platinum - PPDS
    Omaha, Nebraska 68134, United States
  • Midwest Regional Health Services - CCT Research
    Omaha, Nebraska 68144, United States
  • Clinical Research Center of Nevada - ERN - PPDS
    Las Vegas, Nevada 89106, United States
  • Santa Rosa Medical Centers of Nevada - CCT Research
    Las Vegas, Nevada 89119-5483, United States
  • Meridian Clinical Research (Endwell-New York) - Platinum - PPDS
    Endwell, New York 13760, United States
  • IMA Medical Research, PC.
    New York, New York 10036-4103, United States
  • CHEAR Center LLC - ClinEdge - PPDS
    The Bronx, New York 10455-3908, United States
  • Javara Research Inc. - Charlotte - Javara - PPDS
    Charlotte, North Carolina 28210, United States
  • M3 Wake Research, Inc - M3 WR - ERN - PPDS
    Raleigh, North Carolina 27612, United States
  • Velocity Clinical Research - Cleveland - ERN - PPDS
    Cleveland, Ohio 44122, United States
  • Meridian Clinical Research - Cincinnati - Platinum - PPDS
    Springdale, Ohio 45246, United States
  • Tekton Research
    Moore, Oklahoma 73160-1386, United States
  • Velocity Clinical Research - Anderson - ERN - PPDS
    Anderson, South Carolina 29621, United States
  • Velocity Clinical Research - Greenville - ERN - PPDS
    Greenville, South Carolina 29615, United States
  • Trial Management Associates LLC - ERN - PPDS
    Myrtle Beach, South Carolina 29572-4612, United States
  • Velocity Clinical Research - Spartanburg - ERN - PPDS
    Spartanburg, South Carolina 29303-4225, United States
  • New Phase Research &amp; Development
    Knoxville, Tennessee 37909, United States
  • Benchmark Research - Austin - HyperCore - PPDS
    Austin, Texas 78705, United States
  • Tekton Research - Beaumont - Platinum - PPDS
    Beaumont, Texas 77706, United States
  • Zenos Clinical Research
    Dallas, Texas 75230, United States
  • Milton Haber, M.D.
    Laredo, Texas 78041, United States
  • Sun Research Institute
    San Antonio, Texas 78215-1922, United States
  • Cope Family Medicine - Ogden Clinic
    Bountiful, Utah 84010-4862, United States
  • CCT Research at Springville Dermatology
    Springville, Utah 84663, United States
  • Javara Inc./Privia Medical Group INC
    Forest, Virginia 24551, United States
  • Meridian Clinical Research - Family Practice Ports - Portsmouth - Platinum - PPDS
    Portsmouth, Virginia 23703, United States
09

References and documents

Publications

  • Goswami J, Cardona JF, Caso J, Hsu DC, Simorellis AK, Wilson L, Dhar R, Wang X, Kapoor A, Collins A, Righi V, Lan L, Du J, Zhou H, Stoszek SK, Shaw CA, Reuter C, Wilson E, Das R. Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged >/=50 Years. Clin Infect Dis. 2026 Apr 30;82(4):e855-e862. doi: 10.1093/cid/ciaf515. PubMed 40988124 ↗
  • Goswami J, Cardona JF, Hsu DC, Simorellis AK, Wilson L, Dhar R, Tomassini JE, Wang X, Kapoor A, Collins A, Righi V, Lan L, Du J, Zhou H, Stoszek SK, Shaw CA, Reuter C, Wilson E, Miller JM, Das R; study investigators. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. Lancet Infect Dis. 2025 Apr;25(4):411-423. doi: 10.1016/S1473-3099(24)00589-9. Epub 2024 Nov 25. PubMed 39608389 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Nov 2024, 31 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

Of 40 industry-sponsored phase 3 interventional studies under Virus Diseases, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 24. This study's 31 months is above that.

Counting every sponsor, half of 57 studies reached it within 14 months; a quarter within 8 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2022
First posted
Apr 15, 2022
StartActual
Apr 1, 2022
Primary completionActual
Nov 8, 2024
CompletionActual
Nov 8, 2024
Results first posted
Dec 30, 2025
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05330975
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Apr 15, 2022
Start date
Apr 1, 2022
Primary completion
Nov 8, 2024
Completion
Nov 8, 2024
Results posted
Dec 30, 2025
Last update
Dec 30, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: mRNA-1345 respiratory syncytial virus vaccine · mRNA-1273.214 COVID-19 vaccine

Start the discussion